Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Regeneron, J&J, AstraZeneca Pull Plug On NGF Inhibitors In Development For Pain Indications

This article was originally published in The Pink Sheet Daily

Executive Summary

The three companies' decisions were spurred by concerns about potential for the bone disorder avascular necrosis.
Advertisement

Related Content

Lilly Shows Off R&D Progress With A Pain Franchise Built On New Mechanisms
Pfizer/Lilly And J&J Are Readying NGF Inhibitors For Phase III
Anti-NGFs Advisory Committee Postponed As FDA Reviews New Information
Safety Of Anti-NGFs For Osteoarthritis Pain To Be Weighed By Advisory Panel
How Biologics Are Powering J&J’s Resurgent Drug Business: An Interview with Jay Siegel
Medimmune Bets on Pain: Why The Large Molecule Specialist Thinks It Can Win
Huge Market Belies The Long And Difficult Road To Novel Pain Therapies
Pfizer To Buy King Pharma For $3.6 billion In Order to Strengthen Pain Franchise
No Relief For Pfizer As It Shuts Down Additional Tanezumab Trials
No Relief For Pfizer As It Shuts Down Additional Tanezumab Trials

Topics

Advertisement
UsernamePublicRestriction

Register

PS071664

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel